1. Home
  2. GOF vs RARE Comparison

GOF vs RARE Comparison

Compare GOF & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GOF
  • RARE
  • Stock Information
  • Founded
  • GOF 2006
  • RARE 2010
  • Country
  • GOF United States
  • RARE United States
  • Employees
  • GOF N/A
  • RARE N/A
  • Industry
  • GOF Finance/Investors Services
  • RARE Biotechnology: Pharmaceutical Preparations
  • Sector
  • GOF Finance
  • RARE Health Care
  • Exchange
  • GOF Nasdaq
  • RARE Nasdaq
  • Market Cap
  • GOF 2.7B
  • RARE 2.6B
  • IPO Year
  • GOF N/A
  • RARE 2014
  • Fundamental
  • Price
  • GOF $15.06
  • RARE $30.04
  • Analyst Decision
  • GOF
  • RARE Strong Buy
  • Analyst Count
  • GOF 0
  • RARE 14
  • Target Price
  • GOF N/A
  • RARE $86.64
  • AVG Volume (30 Days)
  • GOF 789.2K
  • RARE 1.8M
  • Earning Date
  • GOF 01-01-0001
  • RARE 11-04-2025
  • Dividend Yield
  • GOF 15.42%
  • RARE N/A
  • EPS Growth
  • GOF N/A
  • RARE N/A
  • EPS
  • GOF N/A
  • RARE N/A
  • Revenue
  • GOF N/A
  • RARE $610,159,000.00
  • Revenue This Year
  • GOF N/A
  • RARE $19.72
  • Revenue Next Year
  • GOF N/A
  • RARE $23.29
  • P/E Ratio
  • GOF N/A
  • RARE N/A
  • Revenue Growth
  • GOF N/A
  • RARE 26.77
  • 52 Week Low
  • GOF $10.96
  • RARE $25.81
  • 52 Week High
  • GOF $16.76
  • RARE $58.00
  • Technical
  • Relative Strength Index (RSI)
  • GOF 57.51
  • RARE 51.17
  • Support Level
  • GOF $14.98
  • RARE $29.60
  • Resistance Level
  • GOF $15.11
  • RARE $31.70
  • Average True Range (ATR)
  • GOF 0.08
  • RARE 1.22
  • MACD
  • GOF 0.01
  • RARE 0.15
  • Stochastic Oscillator
  • GOF 84.48
  • RARE 60.51

About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest

Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: